Table 1.

Baseline characteristics of the study population by assigned treatment, in the whole sample (n = 490, excludes Olanzanzapine arm)

	Placebo n=123	Paliperidone 3 mg n= 27	Paliperidone 9 mg n=125	Paliperidone 15 g n=115	Missinga
Age, mean (sd, min, max)	37.5 (11.2, 18.0, 63.0)	36.2 (10.9, 19.0, 64.0)	36.0 (10.9, 18.0, 60.0)	37.8 (9.9, 18.0, 62.0)	0 (0)
Male, n (%)	86 (69.9)	81 (63.8)	81 (64.8)	74 (64.3)	0 (0)
Race
Asian, n (%)	28 (22.8)	31 (24.4)	28 (22.4)	29 (25.2)	0 (0)
Black, n (%)	26 (21.1)	27 (21.3)	24(19.2)	28 (24.3)	0 (0)
Other, n (%)	6 (4.9)	7 (5.5)	8 (6.4)	7 (6.1)	0 (0)
White, n (%)	63 (51.2)	62 (48.8)	65 (52.0)	51 (44.3)	0 (0)
Country
North American, n (%)	43 (35.0)	42 (33.1)	47 (37.6)	38 (33.0)	0 (0)
Asia/Pacific, n (%)	37 (30.1)	41 (33.1)	37 (29.6)	37 (32.2)	0 (0)
Europe and other, n (%)	33 (26.8)	34 (26.8)	32 (25.6)	31 (27.0)	0 (0)
Africa, n (%)	10 (8.1)	10 (7.9)	9 (7.2)	9 (7.8)	0 (0)
Systolic blood pressure, mean (sd, min, max)	120.1 (13.8, 89.0, 170.0)	118.2 (12.3, 90.0, 146.5)	119.6 (12.8, 90.0, 156.0)	120.3 (14.8, 95.0, 188.0)	5 (1.0)
Diastolic blood pressure, mean (sd, min, max)	75.8 (9.8, 54.0, 110.0)	74.9 (9.1, 50.5, 100.0)	77.0 (8.7, 55.5, 100.0)	75.9 (9.3, 59.0, 112.5)	5 (1.0)
BMI, mean (sd, min, max)	25.7 (5.6, 16.4, 48.1)	25.7 (5.7, 14.9, 44.6)	25.6 (5.9, 16.4, 55.5)	26.8 (7.7, 16.8, 57.3)	4 (0.8)
SAS score, mean (sd, min, max)	2.4 (4.0, 0.0, 20.0)	2.9 (5.0, 0.0, 23.0)	2.9 (4.7, 0.0, 30.0)	3.2 (5.6, 0.0, 27.0)	6 (1.2)
BARS score, mean (sd, min, max)	0.2 (0.5, 0.0, 2.0)	0.2 (0.6, 0.0, 3.0)	0.3 (0.7, 0.0, 4.0)	0.2 (0.5, 0.0, 2.0)	2 (0.4)
Total PANSS score, mean (sd, min, max)	47.5 (6.6, 33.0, 60.0)	46.4 (7.1, 32.0, 76.0)	48.2 (7.6, 31.0, 69.0)	47.0 (8.2, 0.0, 64.0)	0 (0)
PSS score, mean (sd, min, max)	50.0 (14.1, 20.0, 91.0)	48.5 (14.3, 17.0, 85.0)	49.6 (16.6, 20.0, 90.0)	47.6 (14.9, 20.0, 91.0)	2 (0.4)
pystdy, mean (sd, min, max)	−1672.3 (1632.6, −7626.0, 7)	−1694.2 (1873.2, −7349.0, −3)	−1716.5 (1757.6, −9749.0, −6)	−1970.2 (2085.2, −10412.0, −3)	145 (29.6)